Since May 2026, the Democratic Republic of the Congo has been fighting the second largest Ebola epidemic ever recorded. For most clinics reading this — a family practice in Ohio, a multi-site group in Manchester, a community health centre in Ontario — the honest assessment is that the chance of an Ebola patient walking through your door is very low. Public health agencies say so plainly.
That is not the same as nothing to do. The single lesson that keeps repeating from every imported case in the last decade is that the encounter does not begin in a biocontainment unit. It begins at a front desk, with someone who has a fever and an ordinary-sounding story, being asked — or not asked — one question about where they have been. The preparation that matters is not equipment. It is a question, reliably asked, and a documented path for what happens if the answer is yes.
Here is what the published data actually says, and what a sensible practice does with it.
The outbreak was declared in mid-May 2026. On 17 May 2026, the WHO Director-General determined that the epidemic constituted a Public Health Emergency of International Concern — notably, before convening the International Health Regulations Emergency Committee, which met on 19 May and issued temporary recommendations on 22 May. A second Emergency Committee meeting reported on 28 August 2026.
As of 31 August 2026, the ECDC reported 6,186 confirmed cases and 3,007 deaths in DR Congo. The case fatality ratio has sat close to 48%. Roughly 5,000 cases accumulated in the first 100 days, a trajectory the CDC described as unprecedented and which the UN Secretary-General called the fastest-spreading Ebola epidemic on record.
The geography is heavily concentrated. Six provinces have reported cases, but Ituri alone accounts for about 82% of them:
A note on the figures: WHO, the CDC and the ECDC publish slightly different totals depending on their reporting cut-off, and the numbers move weekly. The ECDC figures above are cited because they carry a per-province breakdown. Treat any single number in this article as a snapshot, and check the sources listed at the end for the current position before you act on it.
Most people's mental model of Ebola comes from the 2014–2016 West Africa epidemic and the outbreaks that followed. Two things make this one behave differently.
It is a species we are less equipped for. This outbreak is caused by Bundibugyo virus, one of the Orthoebolavirus species, with fruit bats the suspected natural reservoir. There is no approved vaccine and no specific approved treatment for Bundibugyo virus disease. Ervebo, the licensed Ebola vaccine, is indicated for Zaire ebolavirus; in May 2026 the WHO recommended against its routine use in this outbreak outside research settings, citing insufficient evidence for this species. Emerging immunologic data suggests it may confer some partial cross-protection, and the WHO has called for a Phase III trial — but as of now, cross-protection is being evaluated, not relied upon. The WHO added the first Bundibugyo-specific diagnostic test to its Emergency Use Listing on 2 July 2026.
The response indicators are not being met. This is the part that explains the spread. The CDC's late-August analysis found nearly every operational target missed: an average of 10.6 contacts identified per case against a target of at least 20; only 15–20% of new cases were previously known contacts, against a target above 90%; 72% of alerts tested against a target above 90%; and safe and dignified burial capacity in only 49% of health zones against a target of 100%. Fifty-nine per cent of deaths occurred outside treatment units, which points to transmission chains nobody has seen. The outbreak is spreading in a region already dealing with a humanitarian crisis, insecurity, dense population and heavy cross-border trade movement.
This is where proportion matters, because it is the part most likely to be reported badly.
Uganda recorded 20 cases between May and June 2026, and declared its outbreak over on 25 August 2026. Outside Africa, the total is three known imported cases: two US citizens medically evacuated to Germany for treatment in May and July 2026, and one case in France on 24 June 2026 — a physician returning from DR Congo who self-reported symptoms to health authorities on arrival at Charles de Gaulle, was isolated immediately and referred to a high-containment facility. No secondary cases resulted from any of them.
That is the system working. It is also the entire argument for front-desk screening: in the French case, the chain was broken by a symptomatic person being identified at the point of arrival rather than three days later in a waiting room.
The WHO assesses risk as very high in DR Congo, high in Uganda and bordering countries, and low at the global level. The ECDC puts the likelihood of infection for people living in the EU/EEA at very low. The WHO continues to advise against travel or trade restrictions on affected countries. The United States has implemented enhanced entry screening, routing air passengers arriving from DR Congo, Uganda and South Sudan through a small number of designated airports — JFK, Washington Dulles, Atlanta and Houston Bush Intercontinental.
For a practice outside the region, the realistic scenario is not an outbreak. It is a single returning traveller, an aid worker, a healthcare worker, or a family member of one, presenting with a fever that looks like a hundred other fevers.
The clinical difficulty with Bundibugyo virus disease is that early illness is unremarkable: fever, headache, muscle pain, fatigue, sore throat. It can progress to vomiting, diarrhoea and unexplained bleeding, but by then the patient has often already been through your waiting room. The incubation period runs 2 to 21 days, which is why exposure history — not appearance — is what triages the patient.
The CDC's Health Alert Network advisory sets out what it asks clinicians to do. In practice it reduces to four steps.
The specifics worth committing to memory:
CDC archive photograph, 1995. Isolation practice has changed considerably since; follow your facility's current protocol.
None of this requires buying anything. It requires four things to be true about your systems, and they are the same four things that would help you in any emerging-infection scenario — measles, mpox, a novel respiratory virus, whatever arrives next.
That last point is worth dwelling on, because it is the one that most often fails. Contact tracing at your end is a records problem, not a clinical one.
The reason we are writing about an outbreak on a practice management blog is that every item on that list is a workflow question, and workflow is what the platform is for.
Practices that already have these habits will not need to do anything special about Ebola. That is rather the point. The clinics that handle an unexpected presentation well are the ones whose ordinary intake process already asks the right question and routes the answer somewhere.
Figures and guidance in this article are drawn from the following, all of which are updated more frequently than this page:
Last reviewed 2 September 2026. This article summarises publicly available public health guidance for practice-management purposes. It is not medical advice and does not replace your facility's infection control protocol, current CDC guidance, or the instructions of your local health department. Case figures change frequently — check the sources above before acting on any number here.
Image credits: electron micrograph, CDC / Dr. Frederick A. Murphy (public domain); isolation ward photograph, CDC Public Health Image Library, 1995 (public domain). Charts and diagrams by GenMed Clinical from ECDC and CDC data.
Home · Blog · Pricing · Support · Privacy
